Amylyx Pharmaceuticals
AMLX20.7505.17% ( +1.020 )
Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative disea...
- Open
- 19.690
- High
- 20.940
- Low
- 19.310
- Prev. Close
- 19.730
- Volume
- 3.55M
- Turnover
- 71.42M
- Avg Price
- 20.103
- Bid/Ask Ratio
- --
- Amplitude
- 8.26%
- 52wk High
- 20.940
- Volume Ratio
- 1.70
- Turnover Ratio
- 4.31%
Amylyx Pharmaceuticals Analyst Rating
View MoreForecast & Rating
Jul 30, 2026Price forecast
$24.8919.95%
Forecast & RatingStrong buy
11analysts
- Strong buy90.91%
- Buy0.00%
- Hold9.09%
- Sell0.00%
- Strong sell0.00%
News
- rttnews · 2 days ago, 03:30 AM
Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX,
- PUBT · Jul 13 at 03:01 PM
Amylyx Chief Legal Officer Gina Mazzariello sells USD 539,362 of common stock
- prnewswire · Jul 7 at 09:32 AM
10:31 ETPost-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight
- Simplywall · Jul 7 at 03:12 AM
Is Amylyx Pharmaceuticals (AMLX) A Bargain Following Russell Index Removals?
- PR Newswire · Jul 3 at 11:15 AM
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- Simplywall · Jun 27 at 11:09 AM
Could Amylyx (AMLX) ALS Safety Data Quietly Reframe Its Neurodegeneration Versus Endocrine Strategy?
